Advertisement
AIM vs URGN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIM is a Buy and URGN is a Hold.
AIM's RSI Oscillator ascends from oversold territory
The RSI Indicator for AIM moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 38 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for AIM just turned positive on October 15, 2026. Looking at past instances where AIM's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
Following a +4.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where AIM advanced for three days, in 159 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
AIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AIM entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.860) is normal, around the industry mean (2.973). P/E Ratio (-0.240) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (14.859) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. AIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
URGN in downward trend: price dove below 50-day moving average on September 18, 2026
URGN moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend. In 34 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on URGN as a result. In 69 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for URGN turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for URGN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where URGN's RSI Oscillator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
URGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-12.977) is normal, around the industry mean (2.973). P/E Ratio (-17.843) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (11.403) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. URGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
AIM | URGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 47 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 90 | 43 | |
P/E GROWTH RATING 1..100 | 15 | 25 | |
SEASONALITY SCORE 1..100 | 50 | 45 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
URGN's Valuation (6) in the Biotechnology industry is somewhat better than the same rating for AIM (62) in the null industry. This means that URGN’s stock grew somewhat faster than AIM’s over the last 12 months.
URGN's Profit vs Risk Rating (47) in the Biotechnology industry is somewhat better than the same rating for AIM (100) in the null industry. This means that URGN’s stock grew somewhat faster than AIM’s over the last 12 months.
URGN's SMR Rating (100) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that URGN’s stock grew similarly to AIM’s over the last 12 months.
URGN's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for AIM (90) in the null industry. This means that URGN’s stock grew somewhat faster than AIM’s over the last 12 months.
AIM's P/E Growth Rating (15) in the null industry is in the same range as URGN (25) in the Biotechnology industry. This means that AIM’s stock grew similarly to URGN’s over the last 12 months.
| AIM | URGN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 89% |
| Momentum ODDS (%) | N/A | 4 days ago 88% |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Advances ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| Declines ODDS (%) | 4 days ago 90% | 4 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AIM’s FA Score shows that 1 FA rating(s) are green while URGN’s FA Score has 2 green FA rating(s).
- AIM’s FA Score: 1 green, 4 red.
- URGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AIM’s TA Score shows that 5 TA indicator(s) are bullish while URGN’s TA Score has 4 bullish TA indicator(s).
- AIM’s TA Score: 5 bullish, 2 bearish.
- URGN’s TA Score: 4 bullish, 5 bearish.
Price Growth
AIM (@Biotechnology) experienced а -5.46% price change this week, while URGN (@Biotechnology) price change was -3.99% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
AIM is expected to report earnings on Nov 16, 2026.
URGN is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AIM and
Correlation & Price change
A.I.dvisor indicates that over the last year, AIM has been loosely correlated with URGN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AIM jumps, then URGN could also see price increases.
| Ticker / NAME | Correlation To AIM | 1D Price Change % | ||
|---|---|---|---|---|
| AIM | 100% | -5.29% | ||
| URGN - AIM | 39% Loosely correlated | -0.93% | ||
| RKTO - AIM | 33% Loosely correlated | +1.39% | ||
| RLYB - AIM | 30% Poorly correlated | +0.37% | ||
| SGMT - AIM | 30% Poorly correlated | -0.40% | ||
| LIMN - AIM | 28% Poorly correlated | -0.32% | ||
More | ||||